ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2416

Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue

Ayako Kubota, Toru Suguro, Masayuki Sekiguchi and Kazuaki Tsuchiya, Toho University Omori Medical Center, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, histopathologic, rheumatoid arthritis (RA) and synovium

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies comparing histopathological changes in the synovial tissue in the same RA patients between before and after biologics treatment. We examined biologics impacts on RA synovial tissues based on pathological findings in them collected during surgeries for the same patient before and after biological drug usage.

Methods:

Synovial tissues were collected from 28 RA joints before and after biologics. The average age and disease duration of the study subjects were 63.8 and 20.9, respectively. Histopathological changes in the synovial tissues were compared based on Rooney’s score, and presence or absence of fibrinoid degeneration, proliferation of villi and plasma cell infiltration in the subsynovial tissue. We examined correlation between pathological findings in RA synovium and disease activity under biologics. Disease activity was assessed by CDAI. Etanercept, Infliximab, Tocilizumab, Adalimumab and Abatacept was used as biological drug for 16, 5 ,3 ,2 and 2 joints respectively.

Results:

Rooney score between before and after biological drug usage improved from 28.4 to 12.3 showing significant difference. Significant improvement in Rooney score was observed in all items. Fibrinoid degeneration was observed in 25 cases (89.3%) and 5 cases (17.9%) before and after biologics treatment, respectively, demonstrating a significant reduction with biologics treatment. Proliferation of villi was observed in 27 cases (96.4%) and 10 (35.7%) before and after biologics treatment, respectively, demonstrating a significant reduction with biologics treatment. Plasma cell was observed in 24 cases (85.7%) and 15 (53.6%) before and after biologics treatment, respectively, demonstrating a significant reduction with biologics treatment. After biologics treatment, Rooney’s scores in the remission, low disease activity and moderate disease activity were 9.0,10.2 and 15.6, respectively, showing a statistically significant difference. In addition, the moderate disease activity had significantly higher scores in perivascular lymphocytic infiltration, lymphoid follicle and lymphocyte infiltration compared to the remission and low disease activity.

Conclusion:

The study results demonstrated that biologics treatment significantly ameliorated inflammatory changes in the synovial lining layers and sublining layers. In addition, the results suggested that histopathological findings in the subsynovial tissue reflected disease activity.


Disclosure: A. Kubota, None; T. Suguro, None; M. Sekiguchi, None; K. Tsuchiya, None.

To cite this abstract in AMA style:

Kubota A, Suguro T, Sekiguchi M, Tsuchiya K. Histopathological Change Caused By Biological Treatment in Rheumatoid Arthritis Synovial Tissue [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/histopathological-change-caused-by-biological-treatment-in-rheumatoid-arthritis-synovial-tissue/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/histopathological-change-caused-by-biological-treatment-in-rheumatoid-arthritis-synovial-tissue/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology